Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping by Kelly-Hope, Louise et al.
Kelly-Hope et al. Parasites & Vectors 2014, 7:307
http://www.parasitesandvectors.com/content/7/1/307SHORT REPORT Open AccessInnovative tools for assessing risks for severe
adverse events in areas of overlapping Loa loa
and other filarial distributions: the application of
micro-stratification mapping
Louise A Kelly-Hope1*, Jorge Cano2, Michelle C Stanton1, Moses J Bockarie1 and David H Molyneux1Abstract
Background: The wide distribution of Loa loa infection (loiasis) throughout the Democratic Republic of Congo
(DRC) is a major obstacle to the plans to eliminate onchocerciasis and lymphatic filariasis (LF) because the standard
drug regime is dependent on ivermectin, which cannot be used in co-endemic areas due to the risk of severe
adverse events (SAEs). A better understanding of the micro-epidemiology, overlapping low and high risk areas, and
how they relate to SAEs is critical to ensure safe and effective treatment.
Findings: Based on published data from the Bas Congo Province in DRC, this study used geographical information
systems (GIS) to re-map and analyse onchocerciasis and loiasis prevalence (<20%, 20 to 40%, >40%) at 144 sites in
relation to health district areas reporting SAEs. The new maps highlighted the contrasting patterns of the high
prevalence sites, and significant geographical overlap between low onchocerciasis and high loiasis sites. Statistical
analyses found that sites with medium to high loiasis prevalence were 10 to 16 times more likely to be in a SAE
area than those with low prevalence of loiasis. Sites where both onchocerciasis and loiasis prevalence was >20%
were also associated with SAE areas.
Conclusions: Collaborative efforts between the national onchocerciasis and LF programmes are critical as plans to
scale interventions are moving forward and thus, alternative strategies needed in loiasis co-endemic areas which
may include the new L. loa test and treat strategy using the Cellscope, or interventions such as integrated vector
management, or anti Wolbachia therapy using doxycycline.
Keywords: Loa loa, RAPLOA, Onchocerciasis, Lymphatic filariasis, Democratic Republic of Congo, Severe adverse
events, Micro-stratification mappingFindings
Background
The endemicity and wide distribution of Loa loa filariasis
(loiasis) in Central Africa is a major concern for national
onchocerciasis programmes supported by the African
Programme for Onchocerciasis Control (APOC) and non-
governmental development organisation (NGDOs) due to
the increased risk of severe adverse events (SAEs) associ-
ated with the mass distribution of ivermectin (Mectizan®)* Correspondence: L.Kelly-Hope@liverpool.ac.uk
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article, unless otherwise stated.[1,2]. L. loa is transmitted to humans by Tabanid flies of
the genus Chrysops spp. which are predominately con-
fined to the tropical forests of Africa. Although most L.
loa infected individuals are asymptomatic, infection can
cause tropical eye worm, or Calabar swelling; progressive
neurologic decline, encephalopathy and death have been
reported in individuals after taking ivermectin for oncho-
cerciasis. Individuals with high L. loa microfilarial (Mf)
densities of ≥ 30,000 (Mf/ml blood) are considered to be
most at risk of SAEs [3].
APOC has targeted the control of onchocerciasis (river
blindness) in Africa since 1995 using ivermectin, which
is an effective microfilaricide (donated by Merck & Co.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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lus parasite and transmitted to humans by river breeding
Simulium blackflies [5]. Infection can result in visual im-
pairment or blindness and serious skin disease including
sub-cutaneous nodules where adult worms reside. Over
the past decade the community-directed treatment with
ivermectin (CDTi) strategy has been used to target meso-
hyperendemic areas, defined by community nodule preva-
lence ≥20% using the rapid epidemiological mapping of
onchocerciasis (REMO) survey tool [6]. The CDTi priority
maps have been used extensively by national programmes
to define project areas, however, now as APOC moves its
focus from the ‘control’ to the ‘elimination’ of onchocercia-
sis [7,8] significant challenges arise, particularly in areas
hypo-endemic <20% for onchocerciasis where L. loa trans-
mission occurs [9].
Defining the extent of loiasis co-endemicity on a large
scale has been possible by the development of the rapid
assessment procedure for loiasis (RAPLOA) [10,11],
which was able to correlate the prevalence of eye worm
history (most recent episode lasting < 7 days) with the L.
loa microfilaraemia [12]. Communities with ≥40% eye
worm history prevalence were considered to be most at
risk of SAEs as this was found to correspond approxi-
mately to 20% Mf prevalence, with 5% of individuals es-
timated to have ≥ 8000 mf/ml, and 2% of individuals ≥
30,000 mf/ml in their blood [10-13]. However, L. loa
prevalence models also indicate that some communities
where >20% of individuals have a history of eye worm
may also be at risk of L. loa encephalopathy as they
harbour similar high L. loa Mf densities [9]. This has im-
portant implications for defining the critical threshold for
safe and effective treatment, and if set at a RAPLOA
prevalence of 20% would substantially reduce the risk of
SAEs. However, this would also mean that a significant
number of individuals would not receive ivermectin and
that transmission would potentially continue challenging
the expectation that onchocerciasis can be eliminated.
Optimising intervention strategies in these RAPLOA 20-
40% meso-endemic areas is critical as the risks are not
clearly defined.
Large-scale REMO and RAPLOA surveys undertaken
across Central Africa over the past decade have pro-
duced broad risk maps, and provided some insights into
the geographical factors and potential challenges associ-
ated with co-endemicity. However, to fully understand
the potential risks, it is important to examine data on a
finer scale as prevalence can vary greatly within a short
distance and according to ecological factors. For example,
onchocerciasis transmission zones are considered to be up
to 20kms from the riverine breeding sites of Simulium
and its tributaries [4,14], while high loiasis transmission
occurs predominately in forest and forest fringe areas.
Recent studies in the Democratic Republic of Congo(DRC) have highlighted these geographical associations,
and the overlapping transmission areas that potentially
pose a risk [15,16].The Democratic Republic of Congo
The DRC is the largest endemic country for onchocerciasis
and loiasis in Central Africa, and has reported SAEs associ-
ated with ivermectin for more than two decades [17]. One
of the most Loa endemic and hence problematic areas has
been the Mayombe area in the Bas-Fleuve District, Bas
Congo Province. Following the launch of CDTi activities in
December 2003, approximately 40 individuals reported
SAEs, 28 of the cases with neurological signs showed L. loa
encephalopathy and 19 cases developed coma with 14
deaths; 7 deaths in Kuimba, 4 in Seke-Banza and 3 in
Boma rural health districts [18,19]. Consequently, the
distribution of ivermectin stopped in January 2004 and
an investigation was undertaken to address the high
case fatality rate. The district appeared to be a high risk
area for L. Loa area with encephalopathy related to Mf
densities. The prevalence of onchocerciasis was found
to be hypo to meso-endemic.
In response to these SAEs, several recommendations
were made, including fine scale REMO and RAPLOA
mapping, and strengthening of the infrastructure and SAE
management. The mapping activity was carried out in
2004–2005, and detailed prevalence maps have recently
been published [20]. The availability of these maps pro-
vides an opportunity to re-examine the onchocerciasis and
loiasis prevalence distributions, identify the overlapping
low and high risk areas, and determine how they geo-
graphically relate to historical co-endemic areas and the
SAEs reported in the Bas Congo Province.Data, maps and analyses
Information related to the areas reporting SAEs in the Bas
Congo Province was based on World Health Organization
(WHO) reports for onchocerciasis control [18,19]. No
village and individual-level data was publically available to
accurately map and publish, therefore only the location
of the Kuimba, Seke-Banza and Boma health districts
were mapped based on the existing boundaries, and
using the geographical information system ArcGIS 10
(ESRI, Redland CA). To account for potential geograph-
ical inaccuracies, a 5 km buffer was set around these
health districts and added to the boundary of each one.
We acknowledge that this is a limitation, however, given
that the location of SAEs and death may be different to
that of transmission and infection, these health districts
boundaries are considered to be important in defining the
high risk or geographical SAE areas within this province,
and will help facilitate the response to any SAEs within
the health facilities.
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in the Bas Congo Province were based on the study
carried out by Tekle et al. [20]. The prevalence of both
diseases was measured simultaneously at 144 sites (vil-
lages) using the REMO and RAPLOA survey tools, and
examined by three levels of endemicity; <20%, 20 to
40%, ≥40%. The published maps were imported into
ArcGIS 10 and each study site/village was digitised and
geo-referenced to recreate the study sites. Prevalence
maps were reproduced, and the specific sites that had
both low loiasis and onchocerciasis prevalence (<20%;
hypoendemic), or both medium- high prevalence (≥20%;
meso-hyperendemic) were highlighted and examined in
relation to the historical overlapping transmission zone
by Fain [21], which was recently reproduced and pub-
lished [16].
All prevalence distributions were examined in relation
to the Kuimba, Seke-Banza and Boma health districts and
referred to as SAE areas. For each of the three prevalence
levels, the number of study sites that geographicallyMatadi
A Loiasis < 20% B Loiasis >20 to 40%
D Onchocerciasis < 20% E Onchocerciasis >20 
Figure 1 Geographical patterns of loiasis and onchocerciasis prevalen
shading indicates SAE areas. Yellow dots indicate loiasis prevalence A. <20%
prevalence D. <20% E. 20 to 40% F. >40%.overlapped in these three SAE areas were quantified and
compared to those sites that did not. Statistical differences
between the prevalence levels in and out of SAE areas
were first examined using the Pearson’s Chi-squared test
with p-values < 0.05 considered significant. A univariate
logistic regression model was then fitted to the binary
SAE area data in R software to estimate the odds ratios
(OR) and 95% confidence intervals (CIs) of a site being in
a SAE area.
Filarial distributions associated with SAEs
The location of the three health districts reporting SAEs
and the different geographical patterns of the loiasis and
onchocerciasis prevalence levels are shown in Figure 1.
Overall, a statistically significant difference was found
between the three loiasis prevalence levels and the ex-
tent to which the sites occurred in and out of the de-
fined SAE areas (p-values <0.01), whereas no significant
difference was found between the onchocerciasis preva-
lence levels and the SAE areas (p-value = 0.75) (Table 1).to 40%
C Loiasis > 40%
F Onchocerciasis > 40%
Loiasis
Onchocerciasis
SAE areas
Congo River
ce levels in relation to health districts reporting SAEs. Grey
B. 20 to 40% C. >40%. Brown dots indicate onchocerciasis
Table 1 Summary of prevalence distribution by status of
SAE area
SAE area
Yes No
N % N (%) Total p-value
Loiasis
0-20% 4 5% 67 95% 71
20-40% 21 49% 22 51% 43
> 40% 11 37% 19 63% 30 <0.01
Onchocerciasis
0-20% 18 25% 55 75% 73
20-40% 10 29% 24 71% 34
> 40% 8 21% 29 78% 37 0.75
Overlapping prevalences
Nil 22 24% 68 76% 90
<20% 0 0% 27 100% 27
≥20% 14 52% 13 48% 27 <0.01
Total 36 108 144
Contingency table, plus p-value from a Pearson’s Chi-squared test.
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The sites with low loiasis <20% (n = 71) had the least risk,
and predominately occurred in the north and eastern
areas of the Congo River (Figure 1A), with only 4 sites
(5%) found in SAE areas (Table 1). In contrast, the greatest
risk occurred in sites with medium loiasis 20 to 40%, (n =
43), which was predominantly in the central area, with
half the sites in the defined SAE areas (n = 21; 49%)
(Figure 1B). Compared to the low loiasis sites the odds of
a site with loiasis 20 to 40% being in the SAE area was 16
times higher (OR 15.99, 95% CI 5.41-59.48) as shown inTable 2 Regression model
Odds ratio 95% CI p-value
Loiasis
0-20% - - -
20-40% 15.99 (5.41, 59.48) <0.01
≥ 40% 9.70 (2.96, 38.28) <0.01
Onchocerciasis
0-20% -
20-40% 1.27 (0.50, 3.13) 0.60
≥ 40% 0.84 (0.31, 2.12) 0.72
Overlapping prevalences
Nil - - -
<20% 0.00 0.99
≥20% 3.33 (1.36, 8.26) 0.01
Results obtained by fitting univariate logistic regression models to the SAE
area data.Table 2. Similarly, sites with high loiasis ≥40% (n = 30) had
a greater risk with approximately one third of sites (n = 11;
37%) found in SAE areas (Figure 1C), and the odds of be-
ing in the SAE area was 10 times higher (OR 9.7, 95% CI
2.96-38.28) compared to low loiasis sites (Table 2).
Onchocerciasis prevalence
The sites with low onchocerciasis prevalences <20% (n =
73) were more widely distributed, predominately found in
the western area of the Congo River (Figure 1D), with 18
sites (25%) found in SAE areas (Table 1). Notably, the low
prevalence onchocerciasis areas geographically overlapped
those with medium to high loiasis endemicity (Figure 1B,
C, D). This differed from the sites with medium onchocer-
ciasis 20 to 40% (n = 34), which were broadly distributed
in the central and eastern areas (Figures 1E) where 10 sites
(29%) were found in SAE areas. In contrast, the high on-
chocerciasis ≥40% sites (n = 37) were found in close prox-
imity to the Congo River with 10 sites (29%) in SAE areas,
and found to predominately overlap with medium level
prevalence loiasis areas (Figure 1F). Overall, the propor-
tion of onchocerciasis sites overlapping in SAE areas was
low and no statistically significant relationship was found
in the logistic regression model (Table 2).
Overlapping high and low risk areas
Of the 144 study sites, 90 sites had a combination of low
or high prevalence, with 27 sites recording low <20%
prevalence, and 27 sites recording medium to high >20%
prevalence of both diseases. Statistically significant dif-
ferences were found between the different combinations
of prevalence and the extent to which sites occurred in
and out of the SAE areas (Table 1). The majority of low
prevalence sites occurred in the north and eastern areas
of the Congo River region with no sites found in SAE
areas (Figure 2A).
In contrast, sites with high ≥20% overlapping preva-
lence, occurred mainly in close proximity to the Congo
River with 15 sites (60%) found in SAE areas (Figure 2B).
Regression models suggest a significant relationship with
the overlapping high prevalence sites, however, this risk
cannot be fully quantified as models that combine both
loiasis and onchocerciasis prevalence (both linearly, and
with the inclusion of an interaction term) result in on-
chocerciasis prevalence being non-significant.
The comparison with historical overlapping transmis-
sion maps defined by Fain [21], (Figure 2C), showed a
significant geographical overlap with the sites with high
prevalence of both diseases, as well as the SAE areas
(Figure 2D).
Conclusions
These findings highlight that medium to high RAPLOA
areas were most significantly associated with defined SAE
Loiasis and onchocerciasis
SAE areas
Congo River
Outline of  co -endemic zone 
(Fain 1974)
A Overlap < 20%
Matadi
B Overlap >20%
C Historical overlap (Fain 1974) D Historical and recent overlap
Figure 2 Geographical patterns of overlapping high and low loiasis and onchocerciasis prevalence levels in relation to historical
co-endemicity and health districts reporting severe adverse reactions. Grey shading indicates SAE areas. Yellow dots with brown perimeter
indicate overlapping loiasis and onchocerciasis prevalence A. <20% B. >20%. Historical prevalence and co-endemic zones are outlined in C, and
the geographical relationship between historical co-endemic zones, overlapping prevalences of >20% and SAE areas highlighted in D.
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prevalence areas of L. loa based on the RAPLOA method-
ology. In particular, the sites with 20 to 40% loiasis preva-
lence had the greatest risk, which has major implications
for APOC, as these areas are not usually considered at high
risk of SAEs under ivermectin mass treatment, given that
only a small proportion of the population are estimated
to have high Mf L. Loa densities. A better understanding
of the spatial distribution and relationship between
RAPLOA medium/intermediate (20-40%) prevalence and
high Mf densities is critical in order to maximize the distri-
bution of safe and effective treatment in targeted onchocer-
ciasis areas. It also raises the importance of maintaining a
systematic geo-referenced database comprising village and
individual level information on SAEs, so the local demo-
graphic and environmental risks within DRC can be
understood with the aim of preventing or managing such
catastrophic events.
The re-mapping of these co-endemic sites also pro-
vides new insights into the unique distributions of each
disease. The new maps specifically highlight the con-
trasting spatial patterns of the high prevalence areas,
and in particular the close association of onchocerciasis
>40% with the Congo River. Perhaps most importantlyto the new onchocerciasis ‘elimination’ strategy is the
fact that onchocerciasis hypoendemic areas geographic-
ally coincided with medium to high RAPLOA areas. This
implies that ivermectin MDA cannot be extended to
these drug-naive populations due to the high risk of
SAEs. Therefore, different approaches such as the new
L. loa test and treat strategy using the Cellscope to de-
tect individuals with high Mf densities and exclude
them from treatment may be safer and more econom-
ical [22]. Otherwise alternative interventions such as in-
tegrated vector management (IVM), including targeted
Simulium and Chrysops spp. control, or the use of anti
Wolbachia therapy using doxycycline [23,24] may be es-
sential in order to achieve elimination of onchocerciasis
in this particular area of DRC.
The geographical concordance between historical and
recent high transmission zones (spanning three de-
cades), suggest that these particular co-endemic areas
are relatively stable and linked to distinct local charac-
teristics. Importantly, here we show that they also geo-
graphically coincide with the defined SAE areas, which
are not located in the dense forested areas where high
loiasis dominates [20], nor along the Congo River where
high onchocerciasis dominates - but somewhere in
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neither parasite appears to dominate. This raises import-
ant questions about parasite co-existence and competition
[25], and the role of environmental and demographic fac-
tors influencing the main vectors, and the intensity and
overlap of transmission.
The risk of SAEs must also be assessed in the context
of the lymphatic filariasis (LF) programme in DRC,
which is currently conducting baseline prevalence map-
ping in preparation for the scale up of MDA activities.
Standard MDA includes ivermectin and albendazole [2],
however, in areas where LF is co-endemic with L. loa
the national programme will need to implement the rec-
ommended alternative strategy of twice yearly albenda-
zole and bed nets/long-lasting insecticidal nets (LLINs)
in order to reduce the risk of SAEs [26]. In selected
areas further mapping at a micro-level is necessary to
ensure the most appropriate interventions are distrib-
uted to those most at risk. This study provides some
important insights into overlapping filarial infections
and the risk of SAEs, which may help the national LF
programme as it moves to treat millions of people for
LF over the next few years. Coordinated and collabora-
tive efforts between the two filarial elimination pro-
grammes are crucial to their success.
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